BCL9 and plasma cell myeloma: A treatment that targets mir-30-5p and inhibits BCL9 was shown to reduce tumor burden and metastatic potential in a human multiple myeloma cell xenograft model in mice, which affects the orthopedic diseases of mice irreversibly [25, 26].